Pathology of hereditary breast cancer

Modern Pathology

Volumn 23, Issue , 2010, Pages S46-S51

  Da Silva, Leonard ^a   Lakhani, Sunil R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

BRCA1; BRCA2; BRCAX; Breast; Hereditary cancer

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; BRCAX PROTEIN; CHECKPOINT KINASE 2; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CARCINOMA; CANCER MORPHOLOGY; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CELL FUNCTION; CLINICAL DECISION MAKING; DISEASE SEVERITY; DNA REPAIR; FAMILIAL CANCER; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GERM LINE; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MISSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS;

EID: 77951988898     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.37     Document Type: Article

References (54)

1. Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990;131:961-972.
2. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
3. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792.
4. Easton D, Ford D, Peto J. Inherited susceptibility to breast cancer. Cancer Surv 1993;18:95-113.
5. Lynch ED, Ostermeyer EA, Lee MK, et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 1997;61:1254-1260.
6. McKinnon PJ. ATM and ataxia telangiectasia. EMBO Rep 2004;5:772-776.
7. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006;25: 5912-5919.
8. Rahman N, Scott RH. Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 2007;16(Spec No. 1):R60-R66.
9. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007;39:165-167.
10. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008;40:17-22.
11. Hall JM, Lee MK, Newman B, et al. Linkage of earlyonset familial breast cancer to chromosome 17q21. Science 1990;250:1684-1689.
12. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-2090.
13. Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998;83:2335-2345.
14. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011-2017.
15. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology 2002;34:309-314.
16. Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutationassociated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007; 31:121-128.
17. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-1485.
18. Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005;18: 1305-1320.
19. Honrado E, Osorio A, Milne RL, et al. Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol 2007;20: 1298-1306.
20. Honrado E, Osorio A, Palacios J, et al. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 2006;25:5837-5845.
21. Honrado E, Osorio A, Palacios J, et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol 2005;23:7503-7511.
22. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.Clin Cancer Res 2000; 6:782-789.
23. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90: 1138-1145.
24. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-5180.
25. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20:2310-2318.
26. Marcus JN, Watson P, Page DL, et al. Pathology and heredity of breast cancer in younger women. J Natl Cancer Inst Monogr 1994;86:23-34.
27. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
28. Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9(10 Part 1):3606-3614.
29. Quenneville LA, Phillips KA, Ozcelik H, et al. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 2002;95:2068-2075.
30. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108: 171-182.
31. Simpson PT, Reis-Filho JS, Lambros MB, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 2008;215:231-244.
32. Freneaux P, Stoppa-Lyonnet D, Mouret E, et al. Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer 2000;83:1318-1322.
33. Vaziri SA, Tubbs RR, Darlington G, et al. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol 2001;54:259-263.
34. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-835.
35. Palacios J, Honrado E, Osorio A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005; 90:5-14.
36. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005;11:4003-4011.
37. Pinilla SM, Honrado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006;99:85-90.
38. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-2132.
39. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4.
40. Gaedcke J, Traub F, Milde S, et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 2007;20:864-870.
41. Albiges L, Andre F, Balleyguier C, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol 2005;16:1846-1847.
42. Collins LC, Martyniak AJ, Kandel MJ, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 2009;33:1093-1097.
43. Farshid G, Balleine RL, Cummings M, et al. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol 2006;30: 1357-1366.
44. James PA, Doherty R, Harris M, et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 2006;24:707-715.
45. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295: 1379-1388.
46. Lauge A, Lefebvre C, Laurent-Puig P, et al. No evidence for germline PTEN mutations in families with breast and brain tumours. Int J Cancer 1999;84:216-219.
47. Balleine RL, Murali R, Bilous AM, et al. Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology 2006;49:523-532.
48. Cybulski C, Huzarski T, Byrski T, et al. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin Genet 2009;75:72-78.
49. Easton DF, Pooley KA, Dunning AM, et al. Genomewide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-1093.
50. Lovelock PK, Healey S, Au W, et al. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 2006;43:74-83.
51. Spurdle AB, Lakhani SR, Healey S, et al. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis-a report from the kConFab Investigators. J Clin Oncol 2008;26:1657-1663.
52. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005;5:388-393.
53. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434: 913-917.
54. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921.